1. Home
  2. OPENL vs HUMAW Comparison

OPENL vs HUMAW Comparison

Compare OPENL & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Opendoor Technologies Inc

OPENL

Opendoor Technologies Inc

N/A

Current Price

$0.29

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

N/A

Current Price

$0.06

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPENL
HUMAW
Founded
N/A
2004
Country
United States
United States
Employees
1042
184
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OPENL
HUMAW
Price
$0.29
$0.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
200.7K
14.2K
Earning Date
N/A
03-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.04
52 Week High
$1.25
$0.60

Technical Indicators

Market Signals
Indicator
OPENL
HUMAW
Relative Strength Index (RSI) 39.89 49.37
Support Level $0.21 $0.08
Resistance Level $0.51 $0.12
Average True Range (ATR) 0.04 0.01
MACD -0.01 -0.00
Stochastic Oscillator 26.87 50.94

Price Performance

Historical Comparison
OPENL
HUMAW

About OPENL Opendoor Technologies Inc

Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital-light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: